THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.3] ID: TIP-MED-000235

Solifenacin Succinate

Active Ingredient / Scientific Identity: Solifenacin Succinate • Class: Urinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anticholinergic Bladder Spasmolytic)

⚖️ Compare Profile
Generic / Entity NameSolifenacin Succinate ([12.3])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassUrinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anticholinergic Bladder Spasm
Available Dosage FormsOral Film-Coated Tablets: 5 mg, 10 mg
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Dosing depends on severe renal impairment! In severe CKD (CrCl ≤30 mL/min), exposure increases by 2.1-fold—do NOT exce
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Solifenacin Succinate (TIP-MED-000235, Reference Code [12.3]) is classified under Urological & Renal Stone Medicines (Ch 12) as a Urinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anticholinergic Bladder Spasmolytic). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.3], p. 156): Soliten (Ranbaxy/Sun Pharma), Vesicare (Astellas), Bispec (Dr. Reddy's), Solicept (Lupin), Flotros — Strengths & Dosage Forms: Oral Film-Coated Tablets: 5 mg, 10 mg
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.3], p. 156): Soliten (Ranbaxy/Sun Pharma), Vesicare (Astellas), Bispec (Dr. Reddy's), Solicept (Lupin), Flotros — Strengths & Dosage Forms: Oral Film-Coated Tablets: 5 mg, 10 mg
Dosage Forms & Available Strengths:
Oral Film-Coated Tablets: 5 mg, 10 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Urinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anticholinergic Bladder Spasmolytic) acting on target receptor/enzyme pathways in Urological & Renal Stone Medicines (Ch 12): clinical efficacy is mediated via Urinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anticholinergic Bladder Spasmolytic) for Overactive Bladder (OAB) and Detrusor Overactivity presenting with urinary urgency, frequent daytime/nocturnal urination (pollakiuria/nocturia), and urge urinary incontinence..

4. Therapeutic Indications & Evidence-Supported Uses

  • Overactive Bladder (OAB) and Detrusor Overactivity presenting with urinary urgency, frequent daytime/nocturnal urination (pollakiuria/nocturia), and urge urinary incontinence

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: 5 mg once daily; if needed and well tolerated, may be increased to 10 mg once daily (Maximum 5 mg once daily in severe renal impairment or moderate hepatic impairment, or with potent CYP3A4 inhibitors). Follow urologist prescription.

Administration & Meal Timing: With or without food, swallowed whole with water. | Once daily (morning or evening; very long elimination half-life of 45–68 hours provides 24-hour bladder relaxation).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Dosing depends on severe renal impairment! In severe CKD (CrCl ≤30 mL/min), exposure increases by 2.1-fold—do NOT exceed 5 mg once daily! Hepatic: In moderate hepatic impairment (Child-Pugh B), do not exceed 5 mg once daily; contraindicated in severe hepatic impairment (Child-Pugh C).
Elimination & Renal Adjustment:
Renal: Dosing depends on severe renal impairment! In severe CKD (CrCl ≤30 mL/min), exposure increases by 2.1-fold—do NOT exceed 5 mg once daily! Hepatic: In moderate hepatic impairment (Child-Pugh B), do not exceed 5 mg once daily; contraindicated in severe hepatic impairment (Child-Pugh C).
Hepatic Impairment Considerations:
Renal: Dosing depends on severe renal impairment! In severe CKD (CrCl ≤30 mL/min), exposure increases by 2.1-fold—do NOT exceed 5 mg once daily! Hepatic: In moderate hepatic impairment (Child-Pugh B), do not exceed 5 mg once daily; contraindicated in severe hepatic impairment (Child-Pugh C).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Strictly CONTRAINDICATED in Urinary Retention (or high Post-Void Residual [PVR] urine volume >150–200 mL in unoperated BPH!), Uncontrolled Narrow-Angle Glaucoma, Myasthenia Gravis, Severe Gastrointestinal Conditions (toxic megacolon, gastric retention, bowel obstruction), Haemodialysis, Severe Hepatic Impairment, and QTc Prolongation!

Key Clinical Precautions: Renal: Dosing depends on severe renal impairment! In severe CKD (CrCl ≤30 mL/min), exposure increases by 2.1-fold—do NOT exceed 5 mg once daily! Hepatic: In moderate hepatic impairment (Child-Pugh B), do not exceed 5 mg once daily; contraindicated in severe hepatic impairment (Child-Pugh C).

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Dry mouth (xerostomia, 11% at 5 mg, climbing to 28% at 10 mg!), Constipation (5–13%), Blurred vision (accommodation cycloplegia), dry eyes, dyspepsia, urinary tract infection (due to incomplete bladder emptying).
  • Acute Urinary Retention (especially in elderly men with concurrent BPH!), Anticholinergic Cognitive Impairment, Confusion, Memory Loss, Hallucinations, and Delirium in Elderly Patients (especially those with dementia or Parkinson's!), QTc Interval Prolongation and Torsades de Pointes, heat stroke / anhidrosis (reduced sweating during extreme Indian summer heat waves!), faecal impaction.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Cholinesterase Inhibitors for Dementia (Donepezil [Aricep], Rivastigmine, Galantamine): DIRECT PHARMACOLOGICAL CLASH! Solifenacin blocks muscarinic receptors while Donepezil boosts acetylcholine—co-administration worsens dementia and precipitates confusion! (Switch Solifenacin to Mirabegron in any patient taking Donepezil!)
  • Potent CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir): Double Solifenacin plasma AUC—do NOT exceed 5 mg once daily! 3
  • Additive Anticholinergic & QTc Burden: Amitriptyline, Tiotropium/Ipratropium, Antihistamines, Amiodarone, Domperidone

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: 1. Advise taking small sips of water or sucking sugar-free candy for dry mouth (rather than drinking huge 2-litre jugs of water at night, which worsens bladder frequency!). 2. Stop immediately and inform the doctor if urination becomes weak, painful, or stops completely. 3. During peak Indian summer heat (May–June), stay hydrated indoors, as solifenacin reduces sweating.
  • Meal & Clock Timing Instruction: With or without food, swallowed whole with water. (Once daily (morning or evening; very long elimination half-life of 45–68 hours provides 24-hour bladder relaxation).)
  • Missed Dose Protocol: Take the next scheduled tablet the following day; never take two tablets on the same day.
  • Geriatric Dispensing Pearl: Beers Criteria Strong Caution: Antimuscarinic bladder drugs (Oxybutynin, Tolterodine, Solifenacin, Darifenacin) carry a high risk of confusion, falls, constipation, and dementia progression in elderly CGHS patients. In seniors >70 years or anyone with cognitive decline, Mirabegron (a Beta-3 agonist with zero anticholinergic cognitive toxicity) is generally preferred.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 5 mg, 10 mg

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.3] (p. 156)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.